Literature DB >> 8092207

A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.

L Henriksson1, M Stjernquist, L Boquist, U Alander, I Selinus.   

Abstract

OBJECTIVE: Our purpose was to study the efficacy, safety, and acceptability of a new estradiol-releasing (6.5 to 9.5 micrograms per 24 hours) silicone rubber vaginal ring compared with Ovesterin 0.5 mg estriol vaginal pessaries. STUDY
DESIGN: Gynecologic clinical status, vaginal pH, cytologic characteristics, and occurrence of bacteriuria were determined before starting and after 3 and 12 weeks of treatment in 146 postmenopausal women.
RESULTS: Both treatments alleviated the subjective and objective symptoms of estrogen deficiency excellently, and both were equally effective at restoring the vaginal pH to levels normally seen in fertile women (< 5.5). Vaginal cytologic studies showed a significant difference in maturation value in favor of the estradiol-releasing silicone rubber vaginal ring, as measured by the pathologist's assessment of the proliferation of the vaginal mucosa. A total of 77% of users were classified as responders, compared with 39% in the pessary group. Both treatments were well accepted. The administration of the pessary was associated with a significantly higher (p < 0.001) incidence of discomfort than that of the ring, which was given better (p < 0.001) rating by the patients at the 12-week visit. A strong preference (p < 0.001) for the ring was shown by patients with previous experience with pessaries.
CONCLUSION: Treatment of urogenital symptoms in postmenopausal women with an estradiol-releasing vaginal ring is shown to be an effective and safe method, exhibiting advantages over treatment with estriol vaginal pessaries.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092207     DOI: 10.1016/0002-9378(94)90074-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Pharmacokinetics and pharmacodynamics of three dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women.

Authors:  Raimundo Vieira de Oliveira Filho; Natalícia de Jesus Antunes; Jaime de Oliveira Ilha; Ronilson Agnaldo Moreno; Ralph-Steven Wedemeyer; André Warnke; Gilberto De Nucci
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

Review 2.  Assessment of vaginal atrophy: a review.

Authors:  M A Weber; J Limpens; J P W R Roovers
Journal:  Int Urogynecol J       Date:  2014-07-22       Impact factor: 2.894

3.  The development of a quality of life instrument for use with post-menopausal women with urogenital atrophy in the UK and Sweden.

Authors:  S P McKenna; D Whalley; U Renck-Hooper; S Carlin; L C Doward
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

4.  Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world.

Authors:  Kathleen Ridgeway; Elizabeth T Montgomery; Kevin Smith; Kristine Torjesen; Ariane van der Straten; Sharon L Achilles; Jennifer B Griffin
Journal:  Contraception       Date:  2021-10-10       Impact factor: 3.051

Review 5.  Rational prescribing for postmenopausal urogenital complaints.

Authors:  I Milsom
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

Review 6.  Dyspareunia in postmenopausal women: a critical review.

Authors:  A Kao; Y M Binik; A Kapuscinski; S Khalife
Journal:  Pain Res Manag       Date:  2008 May-Jun       Impact factor: 3.037

Review 7.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

Review 8.  Local Oestrogen for Pelvic Floor Disorders: A Systematic Review.

Authors:  M A Weber; M H Kleijn; M Langendam; J Limpens; M J Heineman; J P Roovers
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.